Use of Cystatin C to Assess Kidney Function

Comparison To Current Nephelometric Assay (PENIA) Reveals 23% Bias

August 2011

Previously, the Mayo Clinic renal laboratory used a nephelometric assay for cystatin C. When samples were recently run using both platforms, we found that there was a 23% bias, with the newer PETIA assay being higher than the previous nepholmetric assay or PENIA.

< Previous Slide

Comparison To Current Assay Reveals Bias

Next Slide >

 

Jump to section:

• Introduction
• A Case
• Questions
• What do the kidneys do?
• Why Measure Renal Function?
• How Is Chronic Kidney Disease (CKD) Defined?
• Stages of Chronic Kidney Disease
• Laboratory Assessment of Kidney Function: What Can We Measure?
• Creatinine as a Marker of GFR
• Creatinine as a Marker of GFR: It Works But...
• How Can We Turn the Serum Creatinine Into a Better Estimate of GFR?
• Revised eGFR Equation (ID-MS version)
• eGFR Equation Works, But it's Not Perfect
• What About Cystatin C?
• Mayo Renal Laboratory Cystatin C By Particle Enhanced Turbidometric Immunoassay (PETIA)
• Comparison To Current Nephelometric Assay (PENIA) Reveals 23% Bias
• Cystatin C PENIA Assay Shift (19%)
• Cystatin C eGFR Using Published Equation* Performs Well³
• Cystatin C Equations Categorize Patients Slightly Better Than MDRD eGFR
• Cystatin C Reference Range
• PETIA Cystatin C Reference Range
• Cystatin C: Useful To Confirm Those At Risk Of CKD Progression And Its Complications (REGARDS)⁴
• Cystatin C: CKD Progression and Complications (MESA and CHS)⁵
• Cystatin C in the Acute Hospitalized Setting⁶
• Back to Our Patient
• Potential Interventions
• Conclusions
• References
• Questions?